The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

These glasses allow people with macular degeneration to see complete objects by banishing pesky blind spots using dozens of ...

Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

Vabysmo Product Monograph, December 13, 2024. 2. Song P, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, ...

A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ...

On completion of the scans and tests, he said: “You have early age-related macular degeneration.” When he saw my face fall, he added: “AMD – it’s very common.” My grandmother suffered.

Outlook Therapeutics, Inc. has announced a key development in the treatment of wet age-related macular degeneration (wet AMD) with the National Institute for Health and Care Excellence (NICE ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.